Table 2

Immunohistochemical analysis of tumor cell proliferation (anti-PCNA) and apoptosis (TUNEL) in tumors from animals treated for 11, 18, and 30 days

Therapy% PCNA/Total cellsa Median (range)Pb% TUNEL/Total cellsa Median (range)Pb
Control
11 days92 (87–98)1.4 (1–7)
18 days94 (79–98)0.9 (0–3)
30 days72 (31–94)1.1 (0.5–2)
Gemcitabine
11 days73 (51–80)0.0110 (3–13)0.006
18 days69 (31–75)0.0115 (8–21)0.005
30 days56 (37–67)NSc30 (18–39)0.005
C225
11 days26 (9–85)0.048 (2–21)NS
18 days34 (26–52)0.04d17 (7–18)0.004d
30 days30 (14–41)0.02d39 (23–41)0.004
C225+ gemcitabine
11 days19 (13–30)0.0000017 (5–14)0.02
18 days7 (3–23)0.00000127 (21–43)0.009
30 days4 (0–6)0.00439 (36–68)0.009d
  • a PCNA- or TUNEL-positive cells were counted in 10 microscopic fields per tumor section at ×100 (0.159 mm2). The total number of cells/field and the number of PCNA- or TUNEL-positive cells in that field were determined to calculate the median percentage in each tumor section.

  • b Control versus the therapy shown.

  • c NS, not significant.

  • d For C225 versus C225 plus gemcitabine, P < 0.008 (unpaired Student’s t test).